Results 161 to 170 of about 2,048,259 (212)

Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis: Ringing in a New Future

Leukemia Research, 2022
Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a rare hematologic malignancy belonging to the category of myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes.
Douglas Tremblay, John Mascarenhas, Jonathan Feld   +2 more
exaly   +2 more sources

SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome–Refractory Cytopenia With Multilineage Dysplasia

Clinical Lymphoma, Myeloma and Leukemia, 2020
BACKGROUND Integrating the proportion of ring sideroblasts and SF3B1 mutation status is required for diagnosis of sideroblastic subgroups in myelodysplastic syndrome (MDS) as proposed by the World Health Organization 2016 classification.
Yalan Yu, Bei Xiong
exaly   +2 more sources

[Ring sideroblasts and iron metabolism].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2020
Ring sideroblasts show abnormal mitochondrial iron accumulation, and their emergence in the bone marrow is a characteristic of sideroblastic anemias (SAs). SAs are a group of heterogeneous congenital and acquired disorders. Congenital SA is a rare disease caused by gene mutations involved in heme biosynthesis, iron-sulfur cluster biosynthesis, and ...
Tohru Fujiwara
openaire   +3 more sources

Splicing Factor SF3B1 Mutations and Ring Sideroblasts in Myelodysplastic Syndromes: A Brazilian Cohort Screening Study

Revista Brasileira De Hematologia E Hemoterapia, 2016
BACKGROUND: Myelodysplastic syndromes (MDS) comprise a group of malignant clonal hematologic disorders characterized by ineffective hematopoiesis and propensity for progression to acute myeloid leukemia.
Rodrigo T. Calado, Felipe Martelli
exaly   +2 more sources

Recent Advances in the Understanding of Myelodysplastic Syndromes With Ring Sideroblasts

British Journal of Haematology, 2016
Myeloid neoplasms with ring sideroblasts are currently categorized within the myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the World Health Organization classification.
Mario Cazzola, Luca Malcovati
exaly   +2 more sources

Myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T) – “2021 update on diagnosis, risk‐stratification, and management”

American journal of hematology/oncology, 2021
Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include myelodysplastic syndromes with RS (MDS‐RS) and MDS/myeloproliferative neoplasm with RS
M. Patnaik, A. Tefferi
semanticscholar   +1 more source

Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts

American journal of hematology/oncology, 2022
Luspatercept, a recombinant activin receptor type IIB fusion protein, traps transforming growth factor-beta (TGF-B) superfamily ligands, decreases SMAD2/3 signaling and enhances late-stage erythropoiesis.
N. Gangat, Deandra Chetram, Kristen B. McCullough, A. Al-Kali, K. Begna, W. Hogan, M. Litzow, J. Foran, Talha Badar, J. Palmer, M. Patnaik, A. Pardanani, A. Tefferi   +12 more
semanticscholar   +1 more source

Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM)

Transfusion, 2022
MDS‐RS patients are characterized by chronic anemia and a low risk of Acute Myeloid Leukemia (AML) progression and they generally become Red Blood Cell (RBC) transfusion dependent (TD).
Claire Jouzier, Amina Cherait, P. Cony-Makhoul, J. Hamel, Mélanie Véloso, S. Thepot, T. Cluzeau, A. Stamatoullas, A. Garnier, A. Guerci-Bresler, S. Dimicoli-Salazar, G. Pica, S. Chéze, Clémence Santana, F. Chermat, P. Fenaux, Sophie Park   +16 more
semanticscholar   +1 more source

Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts

Expert Review of Hematology, 2021
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell diseases characterized by cell dysplasia, ineffective hematopoiesis and risk of transformation to acute myeloid leukemia (AML). The median age of 75 years at diagnosis is associated with the presence of comorbidities, which preclude intensive therapies like allogeneic ...
Felicitas, Schulz, Kathrin, Nachtkamp, Annika, Kasprzak, Norbert, Gattermann, Rainer, Haas, Ulrich, Germing   +5 more
openaire   +2 more sources

Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis

Leukemia and Lymphoma, 2021
Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is characterized by anemia, ring sideroblast erythroid precursors, and persistent thrombocytosis.
R. Komrokji, M. Melody, N. Al Ali, O. Chan, V. Klimek, B. Ball, M. Sekeres, G. Lucas, J. Maciejewski, D. Sallman, E. Padron, A. Kuykendall, T. Lasho, A. Al-Kali, K. Naqvi, D. Steensma, G. Garcia-Manero, M. Patnaik   +17 more
semanticscholar   +1 more source